What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 4.3% in the afternoon session after Canaccord Genuity reiterated its Buy rating...
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated in January.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp wave of year-end tax-loss harvesting has sent many mid-cap and commercial-stage biotech firms into a tailspin. Investors, eager
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital.
The select few that can do all three for many years are often the ones that make you life-changing money.
Free cash flow is one of the most reliable indicators of financial durability.
These businesses not only generate cash but reinvest intelligently to sustain momentum.
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.
